Sartorius Stedim Biotech (DIM.PA)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. This filer's financial year end could not be read from its revenue history, so quarters are labelled by the calendar. Amounts in EUR.

2Y 5Y 10Y All
Quarterly Annual TTM

Revenue Annual

0 1.5B 3B 4.5B Q4 '21: 2.9B Q4 '22: 3.5B Q4 '23: 2.8B Q4 '24: 2.8B Q4 '25: 3B Q4 '21 Q4 '22 Q4 '23 Q4 '24 Q4 '25

Gross Profit Annual

0 700M 1.4B 2.1B Q4 '21: 1.6B Q4 '22: 1.8B Q4 '23: 1.2B Q4 '24: 1.2B Q4 '25: 1.3B Q4 '21 Q4 '22 Q4 '23 Q4 '24 Q4 '25

Operating Income Annual

0 350M 700M 1.1B Q4 '21: 865.4M Q4 '22: 995.2M Q4 '23: 449.5M Q4 '24: 370.6M Q4 '25: 525.7M Q4 '21 Q4 '22 Q4 '23 Q4 '24 Q4 '25

Net Income Annual

0 300M 600M 900M Q4 '21: 414.3M Q4 '22: 879.9M Q4 '23: 312.7M Q4 '24: 178.5M Q4 '25: 266M Q4 '21 Q4 '22 Q4 '23 Q4 '24 Q4 '25

Cost of Revenue Annual

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow Annual

0 300M 600M 900M Q4 '21: 701.9M Q4 '22: 612.3M Q4 '23: 746.4M Q4 '24: 815.1M Q4 '25: 692.2M Q4 '21 Q4 '22 Q4 '23 Q4 '24 Q4 '25

Free Cash Flow Annual

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Shares Outstanding Annual

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

EPS TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.